Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Gilberto de Castro (Corresponding Author), Iveta Kudaba, Yi-Long Wu, Gilberto Lopes, Dariusz M Kowalski, Hande Z Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K Laktionov, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony S K Mok, Byoung Chul Cho
Research output: Contribution to journal › Article › peer-review
110Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study'. Together they form a unique fingerprint.